Get the Stockscreener App
0.1643
77.65%
-0.5707
Avenue Therapeutics Inc stock is traded at $0.1643, with a volume of 108.
It is down -77.65% in the last 24 hours and down -77.65% over the past month.
See More
Previous Close:
$0.735
Open:
$0.1642
24h Volume:
108
Relative Volume:
0.20
Market Cap:
$N/A
Revenue:
$1.40M
Net Income/Loss:
$-2.95M
P/E Ratio:
-0.172
EPS:
-0.9554
Net Cash Flow:
$-1.83M
1W Performance:
-77.65%
1M Performance:
-77.65%
6M Performance:
-77.65%
1Y Performance:
-96.88%
1-Day Range:
$0.1642
$0.1642
1-Week Range:
$0.1642
$0.1642
52-Week Range:
$0.1642
$0.735
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.1642 | 0 | 1.40M | -2.95M | -1.83M | -0.9554 |
VRTX
Vertex Pharmaceuticals Inc
|
443.29 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.81 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
802.86 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
325.93 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
308.78 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Carnegie Investment Counsel Increases Stake in Argan, Inc. $AGX - Defense World
Stock List: Research Stocks from Around the World - GuruFocus
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Rare disease drug wins FDA nod as Fortress unit sells voucher for $205M - Stock Titan
ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News
Palvella Therapeutics Announces Proposed Public Offering - GlobeNewswire
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan
Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Announces Pricing of Public Offering - The Manila Times
Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
Anchor Line Partners, LLC and Northwood Investors, LLC secures 98,500 s/f lease Stoke Therapeutics at 245 Fifth Ave. - NEREJ
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
Cap:
|
Volume (24h):